Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors

Abstract

The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 11 / 330,033, filed Jan. 10, 2006, which claims priority from U.S. Provisional Application No. 60 / 643,028, filed Jan. 10, 2005, the contents of each are hereby incorporated by reference.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]This invention was made with government support under grant nos. R37 ES02710 and P01 ES04699, awarded by the National Institute of Environmental Health Sciences of the National Institutes of Health. The government has certain rights in the invention.REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK[0003]NOT APPLICABLEBACKGROUND OF THE INVENTION[0004]Arachidonic acid is released from membrane phospholipids by the enzyme phospholipase A2. This highly unsaturated fatty acid is metabolized through one of three pathways: the cyclooxygenases (“CO...

AI Technical Summary

Benefits of technology

[0015]In a further group of embodiments, the invention provides methods for increasing the effect in a subject of a first enzyme inhibitor having a residence time in the body, wherein the subject is administered a first enzyme inhibitor which first enzyme inhibitor inhibits the activity of an enzyme selected from the group consisting of: (a) cyclo-oxygenase (“COX”)-1, COX-2, 5-lipoxygenase (“5-LOX”), or a combination of these enzymes, and (b) soluble epoxide hydrolase (“sEH”), during the residence time of the first enzyme inhibitor in the body of the subject, the subject is administered a second enzyme inhibitor having a residence time in the body, which second enzyme inhibitor inhibits the activity of an enzyme selected from the group consisting of (c) COX-1, COX-2, 5-LOX, or a combination of these enzymes, and (d) sEH, wherein the combination of said first and second enzyme inhibitors increases the effect of the first enzyme inhibitor over the effect of that inhibitor in the absence of the second enzyme inhibitor, provided that, when said first enzyme inhibitor is from group (a), said second enzyme inhibitor is from group (d) and when said first enzyme inhibitor is from group (b), said second enzyme inhibitor is from group (c). In some embodiments, the subject is administered the first enzyme inhibitor within 4 hours of the subject being administered the second enzyme inhibitor. In some embodiments, the inhibitor of COX-1, COX-2, 5-LOX, or a combination of these enzymes is selected from the group consisting of celecoxib, valdecoxib, lumiracoxib, etoricoxib, rofecoxib and an inhibitor of 5-lipoxygenase activating protein. In some embodiments, the inhibitor of COX-1, COX-2, 5-LOX, or a combination of these enzymes is selected from the group consisting of licofelone and tepoxalin. In some embodiments, the inhibitor of COX-1, COX-2, 5-LOX, or a combination of these enzymes is selected from the group consisting of aspirin, acetaminophen, diclofenac potassium, diclofenac sodium, diclofenac sodium with misoprostol, diflunisal, etodolac, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen sodium, piroxicam, tolmetin sodium, magnesium salicylate, choline salicylate, salsalate, and sodium salicylate. In some embodiments, the inhibitor of sEH has a primary pharmacophore selected from the group consisting of a urea, a carbamate and an amide. In some embodiments, the inhibitor of sEH has a polyether secondary pharmacophore. In some embodiments, the method further comprises administering a cis-epoxyeicosantrienoic acid to said subject. In some embodiments, the method further comprises administering an epoxide of docosahexaenoic acid (“DHA”) or of eicosapentaenoic acid (“EPA”), or an epoxide of DHA and an epoxide of EPA to said subject.

Problems solved by technology

Activated PKR stalls translation by phosphorylation of the translation initiation factors eIF2α, and activated 2′,5′-AS causes mRNA degradation by 2′,5′-oligonucleotide-activated ribonuclease L. These responses are intrinsically sequence-nonspecific to the inducing dsRNA; they also frequently result in apoptosis, or cell death.

Images